Protein clues in kidney disease could predict anemia and heart risks

NCT ID NCT07676526

Not yet recruiting Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study examines how the severity of chronic kidney disease (CKD) affects the breakdown of a protein called FGF23, which is linked to bone health, anemia, and heart problems. Researchers will measure different forms of FGF23 in blood samples from 80 men with CKD stages 3a to 5. The goal is to see if changes in FGF23 cleavage can serve as new biomarkers for complications like anemia and cardiovascular disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify new biomarkers to better predict anemia and heart problems in people with chronic kidney disease.
What could go wrong: This is a small, early-stage observational study, so findings may not lead to immediate clinical changes or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD - CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

CHU de Saint-Etienne

Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.